Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn's Disease (ALOREVA)

Inclusion Criteria: * Signed informed consent. * Patients with Crohn´s disease diagnosed at least 12 months earlier in accordance with accepted clinical, endoscopic, anatomopathological and/or radiologic criteria. * Fulfilling one of the following criteria: * At least, one previous surgery for fistulous disease. * Physical status which discourage liposuction. * Rectovaginal fistula. * Women of a childbearing age. Good general state of health according to the findings of the clinical history and the physical examination. Exclusion Criteria: * Presence of severe proctitis (prominent friability, spontaneous bleeding, multiple erosions, deep ulcers) or dominant active luminal disease requiring immediate therapy, assessed by rectosigmoidoscopy * Patients with CDAI≥201 * Patients with an abscess unless a complete toilet of the area with drainage of the collections and the absence of abscess and other collections is confirmed prior to treatment start * Patients who have received infliximab or any other anti TNF agent in the 8 weeks before the cell treatment administration * Patients who have received tacrolimus or cyclosporine in the 4 weeks before the cell treatment administration * Patients with a history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion * Patients with malignant tumor, except for basal cell or cutaneous squamous cell carcinoma, or patients with a prior history of malignant tumors, unless the neoplastic disease has been i…